Business Context and Reporting Period
Company: Alterity Therapeutics Limited (formerly Prana Biotechnology Limited)
Reporting Period: Fiscal year ended June 30, 2026
Business Overview: Alterity is a development-stage biotechnology company focused on discovering and developing therapeutic drugs for neurodegenerative diseases, specifically targeting Parkinsonian disorders and Multiple System Atrophy (MSA). The company has no commercial products and relies on equity financing and government grants.
Key Asset: ATH434, an oral iron chaperone candidate currently in Phase 3 development for MSA.
Key Financial Metrics (Year Ended June 30, 2026)
| Metric | 2026 (A$) | 2025 (A$) |
|---|---|---|
| Revenue | Nil | Nil |
| Total Income (Interest + Other) | 5,326,672 | 8,087,807 |
| Net Loss | (23,400,949) | (12,147,828) |
| Operating Cash Flow | (22,523,333) | (11,451,248) |
| Cash and Cash Equivalents (End of Period) | 37,317,962 | 33,158,642 |
| Total Assets | 46,019,461 | 46,026,360 |
| Accumulated Deficit | (245,584,285) | (225,888,680) |
| Ordinary Shares Outstanding | 217,508,862 | 9,127,370,686 (Pre-consolidation) |
Note: Financial statements are presented in Australian Dollars (A$). A 50:1 share consolidation occurred in May 2026; comparative figures have been adjusted.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 93% to A$23.4 million from A$12.1 million in 2025, driven by higher operating expenses.
- Expense Growth:
- R&D Expenses: Increased 22% to A$17.6 million due to the initiation of studies supporting Phase 3 activities.
- G&A Expenses: Increased 92% to A$10.5 million, primarily due to increased staffing, audit compliance, and consulting costs.
- Income Fluctuation: Total income decreased due to a reduction in "Other Income" (A$3.6 million vs. A$7.6 million in 2025). The 2025 figure included one-off settlements (Catalent dispute and insurance claim) not present in 2026. However, interest income increased 285% to A$1.7 million due to higher cash balances.
- Capital Structure: The company completed a 50:1 share consolidation. It also raised significant equity capital during the year (net proceeds approx. A$19.3 million) to fund operations.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- ATH434 Progress: In June 2026, the company received FDA End-of-Phase 2 (EOP2) meeting minutes confirming alignment on the Phase 3 trial design for MSA. The company expects to initiate Phase 3 trial activities by year-end 2026.
- Commercial Potential: An independent commercial assessment estimates a potential worldwide peak sales opportunity of US$2.4 billion for ATH434 in MSA if approved.
- Going Concern: Management believes current cash resources (A$37.3 million) are sufficient to fund operations for at least the next 12 months. Continued viability depends on raising additional capital for Phase 3 development.
Key Risks and Contingencies
- Capital Requirements: Substantial additional funding is required for Phase 3 development; failure to secure this could force delays or program discontinuation.
- Clinical Uncertainty: Success in Phase 2 does not guarantee Phase 3 success. Setbacks in clinical trials, regulatory approvals, or manufacturing scale-up could materially harm the business.
- PFIC Status: The company believes it is a Passive Foreign Investment Company (PFIC) for U.S. investors, which may subject them to adverse tax rules.
- Third-Party Reliance: The company lacks internal manufacturing capabilities and relies on third parties for clinical trial execution and drug supply.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the A$37.3 million cash balance against the projected burn rate for the upcoming Phase 3 trial.
- Phase 3 Timeline: Confirm the initiation date of the pivotal Phase 3 trial for ATH434 in MSA, currently targeted for year-end 2026.
- Capital Raising: Monitor upcoming equity offerings or debt financing required to sustain operations beyond the 12-month horizon.
- Regulatory Alignment: Review the specific FDA EOP2 meeting minutes regarding the Phase 3 trial design and endpoints.
- Share Consolidation Impact: Ensure all financial metrics and share counts are viewed on a post-consolidation basis (50:1) to avoid misinterpretation of historical data.